Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 25;7(1):e000943.
doi: 10.1136/bmjophth-2021-000943. eCollection 2022.

Drug-induced corneal deposits: an up-to-date review

Affiliations
Review

Drug-induced corneal deposits: an up-to-date review

Jean-Yves Sahyoun et al. BMJ Open Ophthalmol. .

Abstract

This review assesses different clinical aspects of the various known drug-induced corneal deposits, based on the corneal layer involved (epithelium, stroma and/or endothelium), and based on the drug class. The most well-known condition caused by drug deposits is vortex keratopathy, or corneal verticillata, which is a whorl-like opacity in the corneal epithelium. Vortex keratopathy is commonly caused by certain cationic amphiphilic drugs such as amiodarone, antimalarials, suramin, tamoxifen, chlorpromazine and non-steroidal anti-inflammatory drugs. These deposits usually occur once a certain dose of the drug is reached. Most cases present with mild to moderate symptoms with minimal visual impairment. Most of these deposits resolve automatically, after months to years of drug cessation. Notably, other drug classes can cause deposits in all three layers of the cornea. Chlorpromazine, gold, rifabutin, indomethacin and tyrosine kinase inhibitors can cause stromal deposits, with reduced visual acuity when the anterior stroma is involved. Chlorpromazine and rifabutin can also cause deposits in the endothelial layer of the cornea. Regardless of the type of corneal deposit, local therapies such as topical lubricants or corticosteroids may help improve symptoms. Drug cessation or modification can also be helpful but should be weighed against the systemic risks of the underlying disease.

Keywords: cornea; drugs; ocular surface.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None of the authors has any financial/competing interests to disclose, except M-CR who discloses being a consultant for TALLC, Han-ALL, Santen and an employee of EBSCO. This study does not contain any personal identifying information.

Figures

Figure 1
Figure 1
Amiodarone-induced vortex keratopathy.
Figure 2
Figure 2
Stellate anterior subcapsular cataract and diffuse pigmented corneal deposits secondary to chlorpromazine, seen on slit lamp examination using diffuse (panel A) and focal (panel B) illumination.
Figure 3
Figure 3
(A) Peripheral corneal deposits secondary to rifabutin. (B) Mid-stromal deposits in central cornea secondary to rifabutin.

References

    1. Patel P, Jones K, Friedman DI, et al. . Unexpected etiology in a case of bilateral maculopathy. Case Rep Ophthalmol 2021;12:622–8. 10.1159/000514705 - DOI - PMC - PubMed
    1. Raizman MB, Hamrah P, Holland EJ, et al. . Drug-induced corneal epithelial changes. Surv Ophthalmol 2017;62:286–301. 10.1016/j.survophthal.2016.11.008 - DOI - PubMed
    1. Weiss JS, Moller H, Aldave A. IC3D classification of corneal dystrophies. Edition 2. Cornea, 2015: 117–59. - PubMed
    1. D'Amico DJ, Kenyon KR. Drug-Induced lipidoses of the cornea and conjunctiva. Int Ophthalmol 1981;4:67–76. 10.1007/BF00139581 - DOI - PubMed
    1. Shayman JA, Abe A. Drug induced phospholipidosis: an acquired lysosomal storage disorder. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2013;1831:602–11. 10.1016/j.bbalip.2012.08.013 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources